289 related articles for article (PubMed ID: 23758976)
21. Humanized anti-Sialyl-Tn antibodies for the treatment of ovarian carcinoma.
Eavarone DA; Al-Alem L; Lugovskoy A; Prendergast JM; Nazer RI; Stein JN; Dransfield DT; Behrens J; Rueda BR
PLoS One; 2018; 13(7):e0201314. PubMed ID: 30052649
[TBL] [Abstract][Full Text] [Related]
22. An anti‑TROP2 monoclonal antibody TrMab‑6 exerts antitumor activity in breast cancer mouse xenograft models.
Tanaka T; Ohishi T; Asano T; Takei J; Nanamiya R; Hosono H; Sano M; Harada H; Kawada M; Kaneko MK; Kato Y
Oncol Rep; 2021 Jul; 46(1):. PubMed ID: 34013368
[TBL] [Abstract][Full Text] [Related]
23. The human Müllerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer. Validation using the mAb 12G4.
Kersual N; Garambois V; Chardès T; Pouget JP; Salhi I; Bascoul-Mollevi C; Bibeau F; Busson M; Vié H; Clémenceau B; Behrens CK; Estupina P; Pèlegrin A; Navarro-Teulon I
MAbs; 2014; 6(5):1314-26. PubMed ID: 25517316
[TBL] [Abstract][Full Text] [Related]
24. Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells.
Reim F; Dombrowski Y; Ritter C; Buttmann M; Häusler S; Ossadnik M; Krockenberger M; Beier D; Beier CP; Dietl J; Becker JC; Hönig A; Wischhusen J
Cancer Res; 2009 Oct; 69(20):8058-66. PubMed ID: 19826050
[TBL] [Abstract][Full Text] [Related]
25. A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy.
Fan X; Brezski RJ; Fa M; Deng H; Oberholtzer A; Gonzalez A; Dubinsky WP; Strohl WR; Jordan RE; Zhang N; An Z
Breast Cancer Res; 2012 Aug; 14(4):R116. PubMed ID: 22873525
[TBL] [Abstract][Full Text] [Related]
26. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu.
Cooley S; Burns LJ; Repka T; Miller JS
Exp Hematol; 1999 Oct; 27(10):1533-41. PubMed ID: 10517495
[TBL] [Abstract][Full Text] [Related]
27. Preclinical Evaluation of an Anti-Nectin-4 ImmunoPET Reagent in Tumor-Bearing Mice and Biodistribution Studies in Cynomolgus Monkeys.
Campbell DO; Noda A; Verlinsky A; Snyder J; Fujita Y; Murakami Y; Fushiki H; Miyoshi S; Lacayo S; Cabral E; Yang P; Stover DR; Joseph IB
Mol Imaging Biol; 2016 Oct; 18(5):768-75. PubMed ID: 27122234
[TBL] [Abstract][Full Text] [Related]
28. Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo.
Chang DK; Moniz RJ; Xu Z; Sun J; Signoretti S; Zhu Q; Marasco WA
Mol Cancer; 2015 Jun; 14():119. PubMed ID: 26062742
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapeutic potential of anti-human endogenous retrovirus-K envelope protein antibodies in targeting breast tumors.
Wang-Johanning F; Rycaj K; Plummer JB; Li M; Yin B; Frerich K; Garza JG; Shen J; Lin K; Yan P; Glynn SA; Dorsey TH; Hunt KK; Ambs S; Johanning GL
J Natl Cancer Inst; 2012 Feb; 104(3):189-210. PubMed ID: 22247020
[TBL] [Abstract][Full Text] [Related]
30. Anti-tumor effect against human cancer xenografts by a fully human monoclonal antibody to a variant 8-epitope of CD44R1 expressed on cancer stem cells.
Masuko K; Okazaki S; Satoh M; Tanaka G; Ikeda T; Torii R; Ueda E; Nakano T; Danbayashi M; Tsuruoka T; Ohno Y; Yagi H; Yabe N; Yoshida H; Tahara T; Kataoka S; Oshino T; Shindo T; Niwa S; Ishimoto T; Baba H; Hashimoto Y; Saya H; Masuko T
PLoS One; 2012; 7(1):e29728. PubMed ID: 22272243
[TBL] [Abstract][Full Text] [Related]
31. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance.
Barok M; Isola J; Pályi-Krekk Z; Nagy P; Juhász I; Vereb G; Kauraniemi P; Kapanen A; Tanner M; Vereb G; Szöllösi J
Mol Cancer Ther; 2007 Jul; 6(7):2065-72. PubMed ID: 17620435
[TBL] [Abstract][Full Text] [Related]
32. High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody.
Richter CE; Cocco E; Bellone S; Silasi DA; Rüttinger D; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Am J Obstet Gynecol; 2010 Dec; 203(6):582.e1-7. PubMed ID: 20870202
[TBL] [Abstract][Full Text] [Related]
33. Antitumor activity of an anti-CD98 antibody.
Hayes GM; Chinn L; Cantor JM; Cairns B; Levashova Z; Tran H; Velilla T; Duey D; Lippincott J; Zachwieja J; Ginsberg MH; H van der Horst E
Int J Cancer; 2015 Aug; 137(3):710-20. PubMed ID: 25556716
[TBL] [Abstract][Full Text] [Related]
34. A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies.
Heider KH; Kiefer K; Zenz T; Volden M; Stilgenbauer S; Ostermann E; Baum A; Lamche H; Küpcü Z; Jacobi A; Müller S; Hirt U; Adolf GR; Borges E
Blood; 2011 Oct; 118(15):4159-68. PubMed ID: 21795744
[TBL] [Abstract][Full Text] [Related]
35. CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer.
Wang X; Osada T; Wang Y; Yu L; Sakakura K; Katayama A; McCarthy JB; Brufsky A; Chivukula M; Khoury T; Hsu DS; Barry WT; Lyerly HK; Clay TM; Ferrone S
J Natl Cancer Inst; 2010 Oct; 102(19):1496-512. PubMed ID: 20852124
[TBL] [Abstract][Full Text] [Related]
36. The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity.
Lin J; Spidel JL; Maddage CJ; Rybinski KA; Kennedy RP; Krauthauser CL; Park YC; Albone EF; Jacob S; Goserud MT; Martinez BP; Chao Q; Zhou Y; Nicolaides NC; Kline JB; Grasso L
Cancer Biol Ther; 2013 Nov; 14(11):1032-8. PubMed ID: 24025360
[TBL] [Abstract][Full Text] [Related]
37. MUC1 isoform specific monoclonal antibody 6E6/2 detects preferential expression of the novel MUC1/Y protein in breast and ovarian cancer.
Hartman M; Baruch A; Ron I; Aderet Y; Yoeli M; Sagi-Assif O; Greenstein S; Stadler Y; Weiss M; Harness E; Yaakubovits M; Keydar I; Smorodinsky NI; Wreschner DH
Int J Cancer; 1999 Jul; 82(2):256-67. PubMed ID: 10389761
[TBL] [Abstract][Full Text] [Related]
38. Sym015: A Highly Efficacious Antibody Mixture against
Poulsen TT; Grandal MM; Skartved NJØ; Hald R; Alifrangis L; Koefoed K; Lindsted T; Fröhlich C; Pollmann SE; Eriksen KW; Dahlman A; Jacobsen HJ; Bouquin T; Pedersen MW; Horak ID; Lantto J; Kragh M
Clin Cancer Res; 2017 Oct; 23(19):5923-5935. PubMed ID: 28679766
[No Abstract] [Full Text] [Related]
39. Antitumor activities against breast cancers by an afucosylated anti-HER2 monoclonal antibody H
Tanaka T; Suzuki H; Ohishi T; Kaneko MK; Kato Y
Cancer Sci; 2024 Jan; 115(1):298-309. PubMed ID: 37942574
[TBL] [Abstract][Full Text] [Related]
40. Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition.
Overdijk MB; Verploegen S; van den Brakel JH; Lammerts van Bueren JJ; Vink T; van de Winkel JG; Parren PW; Bleeker WK
J Immunol; 2011 Sep; 187(6):3383-90. PubMed ID: 21832160
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
